Icon
+91 94997 68112
Login Register

OPSYNVI - (10MG;20MG, 10MG;40MG ; Tablet)

MACITENTAN; TADALAFIL Xiamen LP Pharma
10MG;20MG, 10MG;40MG ; Tablet
Less Than $1000 mn
None None
Less Than 5
 None
None None
OPSYNVI is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II-III. Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability.
Yes
OPSYNVI Patent 1 Patent 2 Patent 3
*** *********
********** *** ***** *** ** ********** ******** *********** ****** ************** ************ ********** * **********-********* *********** ************ ********** * ******** ********** ******** ********** *** * **** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.